Independent Medical Education Program
Ionis Pharmaceuticals funds independent medical education to advance clinical care and awareness in hereditary angioedema and severe hypertriglyceridemia.
Funder: Ionis Pharmaceuticals
Due Dates: Rolling (submit at least 60 days before program/event start date)
Funding Amounts: No specified minimum or maximum; award size and duration vary by proposal and available resources.
Summary: Supports independent, unbiased medical education initiatives advancing clinical care in hereditary angioedema and severe hypertriglyceridemia.
Key Information: Only accredited organizations (not individuals or private practice groups) are eligible; all content must be independent of Ionis influence.
Description
The Independent Medical Education (IME) Program by Ionis Pharmaceuticals provides funding for high-quality, evidence-based medical education initiatives that are fully independent of industry influence. The program aims to advance clinical care, disease awareness, and multidisciplinary management in key therapeutic areas—specifically hereditary angioedema (HAE) and severe hypertriglyceridemia (sHTG), including familial chylomicronemia syndrome (FCS). Both accredited and non-accredited educational activities are supported, provided they are controlled solely by the applicant organization, with no input from Ionis regarding content, faculty, or agenda.
